CSIMarket
 
Atreca inc   (BCEL)
Other Ticker:  
 
 

Atreca Inc's Suppliers Performance

BCEL's Supply Chain

 
BCEL Costs vs Sales of Suppliers Growth

More on BCEL Suppliers






  News about Atreca inc Contracts

Atreca Strikes Lucrative $12.5M Asset Sale Deal with Immunome, Boosting Novel Therapeutic Development

Atreca Secures Asset Sale Agreement with Immunome, Potentially Landing $12.5M DealCAMPBELL, Calif. - Atreca, Inc., a preeminent biotechnology firm, has announced a groundbreaking agreement to sell a collection of antibody-related assets and materials to Immunome, Inc. The sale, which showcases Atreca's unique discovery platform and its ability to generate novel therapeutics, could fetch up to $12.5m for the California-based biotech company.Atreca (NASDAQ: BCEL), which operates from Campbell, California, has been consistently developing unique therapeutics through a distinctive discovery platform. The platform is expertly designed to decode the intricacies of the human immune response. Their advanced biotechn...




Atreca Inc's Comment on Supply Chain









BCEL's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Atreca inc 3.15 0.00 -97.76 -
SUBTOTAL 0.00 0.00 0.00 -


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com